IN2015DN03869A - - Google Patents

Info

Publication number
IN2015DN03869A
IN2015DN03869A IN3869DEN2015A IN2015DN03869A IN 2015DN03869 A IN2015DN03869 A IN 2015DN03869A IN 3869DEN2015 A IN3869DEN2015 A IN 3869DEN2015A IN 2015DN03869 A IN2015DN03869 A IN 2015DN03869A
Authority
IN
India
Prior art keywords
compound
tautomer
pyriaone
solvate
superior
Prior art date
Application number
Other languages
English (en)
Inventor
Shoichi Kuroda
Yudai Imai
Takanori Kawaguchi
Keiko Fusegi
Masahiro Bohno
Hajime Asanuma
Tomomichi Chonan
Nagaaki Sato
Souichi MONMA
Shigetada Sasako
Marie MIZUTANI
Shin Itoh
Takumi Okada
Hirofumi Ota
Seishi Ishiyama
Original Assignee
Taisho Pharmaceutical Co Ltd
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd, Nissan Chemical Ind Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of IN2015DN03869A publication Critical patent/IN2015DN03869A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
IN3869DEN2015 2012-11-13 2013-11-12 IN2015DN03869A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012249792 2012-11-13
PCT/JP2013/080517 WO2014077235A1 (ja) 2012-11-13 2013-11-12 2-ピリドン化合物

Publications (1)

Publication Number Publication Date
IN2015DN03869A true IN2015DN03869A (pt) 2015-10-02

Family

ID=50731146

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3869DEN2015 IN2015DN03869A (pt) 2012-11-13 2013-11-12

Country Status (26)

Country Link
US (1) US9695148B2 (pt)
EP (1) EP2921489B1 (pt)
JP (1) JP5963025B2 (pt)
KR (1) KR102160841B1 (pt)
CN (1) CN104768944B (pt)
AU (1) AU2013345930B2 (pt)
BR (1) BR112015010823A2 (pt)
CA (1) CA2891406C (pt)
DK (1) DK2921489T3 (pt)
ES (1) ES2641469T3 (pt)
HK (1) HK1207856A1 (pt)
HU (1) HUE034557T2 (pt)
IL (1) IL238701B (pt)
IN (1) IN2015DN03869A (pt)
MX (1) MX361479B (pt)
MY (1) MY173812A (pt)
NO (1) NO2921489T3 (pt)
NZ (1) NZ707832A (pt)
PH (1) PH12015501056A1 (pt)
PL (1) PL2921489T3 (pt)
PT (1) PT2921489T (pt)
RU (1) RU2662157C2 (pt)
SG (1) SG11201503716RA (pt)
TW (1) TWI591064B (pt)
WO (1) WO2014077235A1 (pt)
ZA (1) ZA201503323B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6048533B2 (ja) * 2014-05-12 2016-12-21 日産化学工業株式会社 2−ピリドン化合物を含有する医薬
JPWO2015174377A1 (ja) * 2014-05-13 2017-04-20 日産化学工業株式会社 2−ピリドン化合物の製造方法
SG11202011883RA (en) 2018-05-31 2020-12-30 Hua Medicine Shanghai Ltd Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and ppar receptor activator, and preparation methods and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275069A (en) 1979-01-22 1981-06-23 The Upjohn Company Anti-diabetic 1,2-dihydro-2-oxo-6-alkyl-nicotinic acids
MXPA01009814A (es) 1999-03-29 2002-04-24 Hoffmann La Roche Activadores de la glucoquinasa.
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
WO2008103185A2 (en) 2006-06-08 2008-08-28 Eli Lilly And Company Substituted carboxamides as group i metabotropic receptor antagonists
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
NZ582664A (en) * 2007-07-17 2012-03-30 Bristol Myers Squibb Co Pyridone gpr119 g protein-coupled receptor agonists
JP2011529483A (ja) 2008-07-29 2011-12-08 ファイザー・インク フッ素化ヘテロアリール
RU2551847C2 (ru) 2009-12-04 2015-05-27 Тайсо Фармасьютикал Ко., Лтд. Производные 2-пиридона
JP2013010750A (ja) * 2011-06-02 2013-01-17 Taisho Pharmaceutical Co Ltd 2−ピリドン化合物を含有する医薬

Also Published As

Publication number Publication date
AU2013345930A1 (en) 2015-06-04
KR102160841B1 (ko) 2020-09-28
ES2641469T3 (es) 2017-11-10
TWI591064B (zh) 2017-07-11
WO2014077235A1 (ja) 2014-05-22
RU2662157C2 (ru) 2018-07-24
ZA201503323B (en) 2016-08-31
DK2921489T3 (en) 2017-10-16
AU2013345930B2 (en) 2017-08-24
EP2921489A4 (en) 2016-04-06
PH12015501056B1 (en) 2015-07-27
RU2015122717A (ru) 2017-01-10
EP2921489A1 (en) 2015-09-23
MX2015005884A (es) 2015-12-09
BR112015010823A2 (pt) 2017-07-11
NO2921489T3 (pt) 2018-02-03
NZ707832A (en) 2019-03-29
MY173812A (en) 2020-02-24
US20160289208A1 (en) 2016-10-06
IL238701A0 (en) 2015-06-30
SG11201503716RA (en) 2015-06-29
CN104768944A (zh) 2015-07-08
EP2921489B1 (en) 2017-09-06
US9695148B2 (en) 2017-07-04
KR20150082301A (ko) 2015-07-15
IL238701B (en) 2018-10-31
HUE034557T2 (en) 2018-02-28
JP5963025B2 (ja) 2016-08-03
PH12015501056A1 (en) 2015-07-27
CA2891406C (en) 2021-03-16
CN104768944B (zh) 2017-03-29
CA2891406A1 (en) 2014-05-22
PT2921489T (pt) 2017-12-01
HK1207856A1 (en) 2016-02-12
MX361479B (es) 2018-12-06
PL2921489T3 (pl) 2018-01-31
JPWO2014077235A1 (ja) 2017-01-05
TW201434826A (zh) 2014-09-16

Similar Documents

Publication Publication Date Title
MY180083A (en) Tetrahydropyrrolothiazine compounds
MX2016006336A (es) Compuestos pirazolopirimidina.
PH12015501993B1 (en) Pyrazole-amide compound and medicinal uses therefor
IN2014MN02106A (pt)
TN2013000253A1 (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
AU2012214029A8 (en) Rorgammat inhibitors
NZ603151A (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
WO2014045162A8 (en) ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS
IN2015DN01119A (pt)
WO2011123536A8 (en) Polycyclic tetracycline compounds
EP2581372A4 (en) CYANOCHINOLINDERIVATE
MX364400B (es) Compuestos de tetraciclina.
IN2012DN02502A (pt)
PH12015501386A1 (en) Tricyclic compounds
MX360699B (es) Derivados de espiro [2.4] heptano puenteado substituidos por piperazina, utilizados como agonistas del receptor alx.
IN2015DN03869A (pt)
GB201020397D0 (en) Compounds
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
WO2015181837A3 (en) Novel compounds as anti-tubercular agents
MX362994B (es) Preparacion farmaceutica que comprende un derivado de aminopirazol.
WO2014106826A3 (en) Anthracycline analogue and uses thereof
IN2014CN04945A (pt)
IN2013DE00880A (pt)
IN2013MU02612A (pt)